CTNNB1 alterations also drive aldosterone-producing adenomas and hyperplasia of the adrenal cortex and recent work has demonstrated that disrupting fibroblast growth factor signaling in these cells may offer therapeutic benefit [112,113]. Here, CTNNB1 is linked to adenoma.